Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | MGLL | Q99685 | 2/20 | 0.48 |
| ▸ | TRPV6 | Q9H1D0 | 2/20 | 0.43 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.43 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.43 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.43 |
| ▸ | PDE2A | O00408 | 3/20 | 0.38 |
| ▸ | POLQ | O75417 | 3/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29349652 | 1.00 | CES2 (0.50) | CES2MGLLTRPV6ORAI1ORAI2 | |
| SCHEMBL24425083 | 0.88 | ALDH1A1 (0.41) | CES2MGLLTRPV6ORAI1ORAI2 | |
| SCHEMBL1670722 | 0.87 | CES2 (0.40) | CES2MGLLTRPV6ORAI1ORAI2 | |
| SCHEMBL1668958 | 0.84 | MGLL (0.42) | CES2MGLLTRPV6ORAI1ORAI2 | |
| SCHEMBL22695061 | 0.83 | CES2 (0.46) | CES2MGLLTRPV6ORAI1ORAI2 | |
| SCHEMBL29689581 | 0.83 | CES2 (0.50) | CES2MGLLTRPV6ORAI1ORAI2 | |
| SCHEMBL1243257 | 0.83 | CES2 (0.50) | CES2MGLLTRPV6ORAI1ORAI2 | |
| SCHEMBL31538169 | 0.83 | CES2 (0.48) | CES2MGLLTRPV6ORAI1ORAI2 | |
| SCHEMBL1396618 | 0.83 | MGLL (0.52) | CES2MGLLTRPV6ORAI1ORAI2 | |
| SCHEMBL581357 | 0.81 | MGLL (0.50) | CES2MGLLTRPV6ORAI1ORAI2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 405 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326709-A1 | THE MICROWAVE-ASSISTED CATALYTIC AMIDATION OF ORGANIC AMINES WITH CARBOXYLIC ACIDS | PURDUE RESEARCH FOUNDATION (US) | 2025-10-23 | — | — | US | claimed |
| US-20250194617-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-06-19 | — | — | US | claimed |
| US-20250169514-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-05-29 | — | — | US | claimed |
| US-20230380457-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-30 | — | — | US | claimed |
| EP-4280882-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2023-11-29 | — | — | EP | claimed |
| US-20230363426-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-16 | — | — | US | claimed |
| US-11793220-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2023-10-24 | — | — | US | claimed |
| US-20220264914-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-08-25 | — | — | US | claimed |
| US-20220225647-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-07-21 | — | — | US | claimed |
| US-20220225646-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-07-21 | — | — | US | claimed |
| CN-111171721-A | Ceramizable ablation-resistant coating and preparation method thereof | 西安近代化学研究所 | 2020-05-19 | — | — | CN | claimed |
| EP-2485678-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | Cornell University (US) | 2012-08-15 | — | — | EP | claimed |
| US-7956184-B2 | Pyridazine compound and use thereof | GILEAD SCIENCES, INC. (US) | 2011-06-07 | — | — | US | claimed |
| WO-2011043817-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY (US) | 2011-04-14 | — | — | WO | claimed |
| US-20100152444-A1 | NOVEL PYRIDAZINE COMPOUND AND USE THEREOF | GILEAD SCIENCES, INC. (US) | 2010-06-17 | — | — | US | claimed |
| US-20100063059-A1 | NOVEL PYRIDAZINE COMPOUND AND USE THEREOF | Puerstinger, Gerhard (AT) | 2010-03-11 | — | — | US | claimed |
| EP-2038275-B1 | NOVEL PYRIDAZINE COMPOUND AND USE THEREOF | GILEAD SCIENCES INC (US) | 2010-01-06 | — | — | EP | claimed |
| EP-2038275-A2 | NOVEL PYRIDAZINE COMPOUND AND USE THEREOF | Gilead Sciences, Inc. (US) | 2009-03-25 | — | — | EP | claimed |
| US-20080199427-A1 | Novel pyridazine compound and use thereof | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2008-08-21 | — | — | US | claimed |
| WO-2008005519-A2 | NOVEL PYRIDAZINE COMPOUND AND USE THEREOF | GILEAD SCIENCES, INC. (US) | 2008-01-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063059-A1 | NOVEL PYRIDAZINE COMPOUND AND USE THEREOF | CYP2F1, HAVCR2, CYP4F2 | CES2 775/4885MGLL 3741/4885TRPV6 2725/4885 |
| US-20100152444-A1 | NOVEL PYRIDAZINE COMPOUND AND USE THEREOF | CYP2F1, HAVCR2, CYP4F2 | CES2 695/4885MGLL 3701/4885TRPV6 2709/4885 |
| US-20250326709-A1 | THE MICROWAVE-ASSISTED CATALYTIC AMIDATION OF ORGANIC AMINES WITH CARBOXYLIC ACIDS | NAAA, OAT, PAM | CES2 1258/4885MGLL 506/4885TRPV6 4435/4885 |
| US-20080199427-A1 | Novel pyridazine compound and use thereof | CYP2F1, HAVCR2, CYP4F2 | CES2 695/4885MGLL 3701/4885TRPV6 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.